Its downregulation is correlated with poor survival outcomes in high-risk patients characterized by elevated tumor mutational burden (TMB) and KEAP1 mutation enrichment (Shimada et al., 2022; Metlay et al., 1995; Zhang F. et al., 2025). Here, KEAP1 is linked to neoplasm.